A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy.
Journal
The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
23
05
2020
accepted:
15
01
2021
revised:
05
12
2020
pubmed:
21
2
2021
medline:
27
1
2022
entrez:
20
2
2021
Statut:
ppublish
Résumé
This meta-analysis was conducted to determine the genotypic effects of rs4149056 and rs2306283 polymorphism in SLCO1B1 gene on myopathy in patients with statin. Studies were searched using multiple databases and selected following inclusion criteria. Two reviewers independently performed data extraction and assessments for risk of bias. Fixed-or-random-effect was applied to pool allele frequency/effects. Mixed-effect logit model was used to pool genotypic effects using individual patient data. Heterogeneity and publication bias were explored. Fourteen studies were pooled for rs4149056; the minor C allele frequency were 15% in Caucasians and 14% in Asians. Six studies were pooled for rs2306283; the minor G allele frequency was 34% in Caucasian and 75% in Asians. Genotypic effects of rs4149056 polymorphism in Caucasians indicated that statin users who carried CC and TC genotypes had a significantly higher risk of myopathy than those who carried TT genotype, with a pooled odds ratio (OR) of 2.9 (95% confidence interval, 1.59, 5.34) and 1.6 (1.20, 2.16), respectively. For subgroup analysis, CC and TC genotypes also suggested a higher risk of myopathy in simvastatin users [OR = 2.8 (1.17, 6.77) and OR = 1.8 (1.15, 2.77), respectively] and in atorvastatin users [OR = 4.0 (1.23, 12.63) and OR = 2.0 (1.11, 3.52), respectively] than those who carried TT genotype. There was no significant association between rs2306283 polymorphism and myopathy in Caucasians and Asians. There was no evidence of publication bias for both polymorphisms.
Identifiants
pubmed: 33608664
doi: 10.1038/s41397-021-00208-w
pii: 10.1038/s41397-021-00208-w
pmc: PMC8159730
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Liver-Specific Organic Anion Transporter 1
0
SLCO1B1 protein, human
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
296-307Références
World Health Organization. Global Health Estimates 2016: disease burden by causbalare, age, sex, by country and by region, 2000–2016. Geneva: World Health Organization; 2018.
Hong Y. Burden of cardiovascular disease in asia: big challenges and ample opportunities for action and making a difference. Clin Chem. 2009;55:1450.
pubmed: 19498049
doi: 10.1373/clinchem.2009.125369
WHO Statistical Information System. Causes of death: mortality and health status. WHO data and statistics. http://www.who.int/research/en/ . Accessed 21 Nov 2019.
Correction to: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140:e649–50.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
pubmed: 21067804
doi: 10.1016/S0140-6736(10)61350-5
Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol. 2012;159:169–76.
pubmed: 21813193
doi: 10.1016/j.ijcard.2011.07.048
Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603.
pubmed: 24016512
pmcid: 4038261
doi: 10.1016/j.ahj.2013.06.004
Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke. 2002;33:2337–41.
pubmed: 12215610
doi: 10.1161/01.str.0000034125.94759.41
Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52c–60c.
pubmed: 16581329
doi: 10.1016/j.amjcard.2005.12.010
Health Product Vigilance Center. Spontaneous reports of ADRs. Nonthaburi: Thai Food and Drug Administration, Ministry of Public Health; 2017.
Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317–24.
pubmed: 22560377
doi: 10.1016/j.ejim.2012.01.004
Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008;337:a2286.
pubmed: 18988647
doi: 10.1136/bmj.a2286
Kitzmiller JP, Binkley PF, Pandey SR, Suhy AM, Baldassarre D, Hartmann K. Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes. Disco Med. 2013;16:45–51.
Arrigoni E, Del ReM, Fidilio L, Fogli S, Danesi R, Di Paolo A. Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins. Int J Mol Sci. 2017;18:104.
pmcid: 5297738
doi: 10.3390/ijms18010104
Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharm Ther. 2012;92:112–7.
doi: 10.1038/clpt.2012.57
Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001;276:35669–75.
pubmed: 11477075
doi: 10.1074/jbc.M103792200
Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharm Ther. 2011;89:210–6.
doi: 10.1038/clpt.2010.255
Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359:789–99.
pubmed: 18650507
doi: 10.1056/NEJMoa0801936
The Royal Dutch Pharmacists Association Pharmacogenetics Working Group. Annotation of DPWG Guideline for atorvastatin and SLCO1B1. 2019. https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf . Accessed 21 Nov 2019.
Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharm. 2012;68:273–9.
doi: 10.1007/s00228-011-1125-1
Melo MS, Balanco L, Branco CC, Mota-Vieira L. Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population. Ann Hum Biol. 2015;42:283–9.
pubmed: 25224634
doi: 10.3109/03014460.2014.955056
Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, et al. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014;41:4631–8.
pubmed: 24668570
doi: 10.1007/s11033-014-3334-z
Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, et al. Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. SpringerPlus. 2016;5:1368.
pubmed: 27606156
pmcid: 4991977
doi: 10.1186/s40064-016-2912-z
Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore). 2015;94:e1268.
doi: 10.1097/MD.0000000000001268
De Keyser CE, Peters BJM, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics. 2014;24:43–51.
pubmed: 24263182
doi: 10.1097/FPC.0000000000000018
Carr DF, O’Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharm Ther. 2013;94:695–701.
doi: 10.1038/clpt.2013.161
Xiang Q, Chen SQ, Ma LY, Hu K, Zhang Z, Mu GY, et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J. 2018;18:721–9.
pubmed: 30250148
doi: 10.1038/s41397-018-0054-0
Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in. SLCO1B1 Pharmacogenomics. 2008;9:19–33.
pubmed: 18154446
doi: 10.2217/14622416.9.1.19
Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S, et al. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J Hum Genet. 2016;61:119–27.
pubmed: 26423926
doi: 10.1038/jhg.2015.115
Little JHJ, eds. The HuGENet™ HuGE review handbook, Version 1.0. Ottawa, Ontario, Canada: University of Ottawa; 2006.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.
pubmed: 19631508
doi: 10.1016/j.jclinepi.2009.06.005
Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395.
pubmed: 27199064
doi: 10.1016/j.jacc.2016.02.071
Thakkinstian A, McKay GJ, McEvoy M, Chakravarthy U, Chakrabarti S, Silvestri G, et al. Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173:1365–79.
pubmed: 21576320
doi: 10.1093/aje/kwr025
Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24:1291–306.
pubmed: 15568190
doi: 10.1002/sim.2010
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
pubmed: 3802833
doi: 10.1016/0197-2456(86)90046-2
Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005;34:1319–28.
pubmed: 16115824
doi: 10.1093/ije/dyi169
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
pubmed: 9310563
pmcid: 2127453
doi: 10.1136/bmj.315.7109.629
Willrich MAV, Kaleta EJ, Bryant SC, Spears GM, Train LJ, Peterson SE, et al. Genetic variation in statin intolerance and a possible protective role for UGT1A1. Pharmacogenomics. 2018;19:83–94.
doi: 10.2217/pgs-2017-0146
Bakar NS, Neely D, Avery P, Brown C, Daly AK, Kamali F. Genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: a case-control study. Clin Pharm Ther. 2017;104:178–87.
doi: 10.1002/cpt.887
Mirošević Skvrce N, Macolić Šarinić V, Šimić I, Ganoci L, Muačević Katanec D, Božina N. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics. 2015;16:803–15.
pubmed: 26086347
doi: 10.2217/pgs.15.47
Ferrari M, Guasti L, Maresca A, Mirabile M, Contini S, Grandi AM, et al. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharm. 2014;70:539–47.
doi: 10.1007/s00228-014-1661-6
Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012;12:233–7.
pubmed: 21243006
doi: 10.1038/tpj.2010.92
Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21:280–8.
pubmed: 21386754
pmcid: 3076530
doi: 10.1097/FPC.0b013e328343dd7d
Linde R, Peng L, Desai M, Feldman D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol. 2010;2:77–84.
pubmed: 21547103
pmcid: 3081682
doi: 10.4161/derm.2.2.13509
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54:1609–16.
pubmed: 19833260
pmcid: 3417133
doi: 10.1016/j.jacc.2009.04.053
Khine H, Yuet WC, Adams-Huet B, Ahmad Z. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J. 2016;179:1–9.
pubmed: 27595674
pmcid: 5014387
doi: 10.1016/j.ahj.2016.05.015
Bai X, Zhang B, Wang P, Wang GL, Li JL, Wen DS, et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharm. 2018;40:492–9.
Sai K, Kajinami K, Akao H, Iwadare M, Sato-Ishida R, Kawai Y, et al. A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab Pharmacokinet. 2016;31:467–70.
pubmed: 27839692
doi: 10.1016/j.dmpk.2016.09.002
Liu JE, Liu XY, Chen S, Zhang Y, Cai LY, Yang M, et al. SLCO1B1 521T>C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharm. 2017;73:1409–16.
doi: 10.1007/s00228-017-2318-z
McKusick’s Online Mendelian Inheritance in Man OMIM®. 2019. http://www.ncbi.nlm.nih.gov/omim . Accessed 30 June 2019.
Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharm Rev. 2011;63:157–81.
pubmed: 21245207
doi: 10.1124/pr.110.002857
Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004;14:429–40.
pubmed: 15226675
doi: 10.1097/01.fpc.0000114750.08559.32
Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15:513–22.
pubmed: 15970799
doi: 10.1097/01.fpc.0000170913.73780.5f
Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharm Exp Ther. 2002;302:804–13.
doi: 10.1124/jpet.302.2.804
DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6:400–8.
pubmed: 23876492
pmcid: 3922121
doi: 10.1161/CIRCGENETICS.113.000099
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharm Ther. 2004;75:415–21.
doi: 10.1016/j.clpt.2003.12.016
Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharm Ther. 2006;79:427–39.
doi: 10.1016/j.clpt.2006.01.011
Thakkinstian A, McEvoy M, Chakravarthy U, Chakrabarti S, McKay GJ, Ryu E, et al. The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol. 2012;176:361–72.
pubmed: 22869612
pmcid: 6483268
doi: 10.1093/aje/kws031
Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61:634–45.
pubmed: 18538260
doi: 10.1016/j.jclinepi.2007.12.011
Namipashaki A, Razaghi-Moghadam Z, Ansari-Pour N. The essentiality of reporting Hardy-Weinberg equilibrium calculations in population-based genetic association studies. Cell J. 2015;17:187–92.
pubmed: 26199897
pmcid: 4503832